AlphaRx Files Patent Application For Oral Drug Delivery System.
RICHMOND, Ontario--(BW HealthWire)--Dec. 13, 2000
AlphaRx Inc. (OTCBB:AHRX) today announced that it has filed a patent application with the U.S. Patent Office to broaden the claims and protection on its drug delivery systems.
The delivery technology covered in this patent application has widespread application for enhanced, targeted delivery of hydrophobic natural compounds.
Self-emulsifying drug delivery systems (SEDDS) are good candidates for the oral delivery of hydrophobic drugs because of their ability to form fine oil-in-water (o/w) emulsions or microemulsions upon mild agitation following dilution in aqueous phase. The extensive research in self-emulsifying drug delivery systems (SEDDS) has led to the design of other lipid self-dispersing vehicles capable of forming drug-loaded fine lipid particles in the gastrointestinal (GI) lumen. These self-microemulsifying or microencapsulated formulations have been proposed as alternatives to conventional SEDDS. All of these formulations produce fine oil droplet/micelle dispersions upon aqueous dilution but can only be administrated in soft or hard gelatin capsules. This presents a serious technological and manufacturing limitation.
AlphaRx's Self-emulsifying Control Released Tablet (SECRET) system has distinct advantages over these SEDDS. They include:
1. The ability to modulate drug release with a reproducible release rate. 2. The ability to protect drugs against decomposition in the GI tract. 3. Compatibility with conventional tablet manufacturing and packaging. 4. They are not pH dependent. 5. Reduced food effect. 6. Once-a-day dosage capability. 7. Application to a wide range of compounds. 8. The possibility of delivering protein and peptide through oral formulations.
"AlphaRx's SECRET system is versatile and offers significant flexibility in the development of suitable dosage formulations (i.e. Immediate Release or Controlled Release) to meet the requirements of specific molecules." Said Mr. Michael Lee, President of AlphaRx. "With more than 40% of new chemical entities exhibiting poor aqueous solubility and complex technical formulation problems, the SECRET system will have an increasing application in the delivery of lipophilic drugs."
The Company now has one issued U.S. patent and four U.S. patent applications relating to its BCD drug delivery systems. Corresponding international patent applications are pending.
AlphaRx is engaged in the development of novel formulations of drugs that are insoluble or poorly soluble in water. AlphaRx's broad product pipeline consists of carefully selected, mainly currently marketed drugs which, through the application of its proprietary BCD drug delivery systems, offer improved medical benefits over existing products as well as strong commercial potential.
For additional information, please visit our web-site at www.AlphaRx.com
FORWARD LOOKING STATEMENTS:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 13, 2000|
|Previous Article:||Cytura Names Thomas Chuckel President and Chief Operating Officer; Cytura Strengthens Executive Management Team with 20 Plus Year Industry Veteran.|
|Next Article:||Viewlocity Designated UCCnet Concept Approved Solution Partner.|